Opinion|Videos|March 17, 2025
Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
Panelists discuss key factors in chimeric antigen receptor T-cell (CAR T) sequencing for relapsed diffuse large B-cell lymphoma, including manufacturing success rates, production turnaround time, and real-world efficacy data. Treatment decisions weigh bridging therapy needs, patient fitness, and center-specific experience with different CAR T products and their reliability.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do efficacy outcomes and manufacturing reliability influence your thinking about optimal sequencing of CAR T for patients with relapsed diffuse large B-cell lymphoma?
- What aspects of the real-world manufacturing and treatment experience have most impacted your approach to second-line therapy decisions?
Advertisement
Related to this article
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Adding fixed-duration epcoritamab to R-CHOP reduced the risk of progression or death by 51% in patients with newly diagnosed DLBCL.
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC
5